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Abstract
Background: Hospitalization for heart failure (HF) is associated with high-in-hospital and short- and long-term post
discharge mortality. Age and gender are important predictors of mortality in hospitalized HF patients. However,
studies assessing short- and long-term risk of death stratified by age and gender are scarce.
Methods: A nationwide cohort was identified (ICD-9 codes 402, 428) and followed through linkage of national
registries. The crude 28-day, 1-year and 5-year mortality was computed by age and gender. Cox regression models
were used for each period to study sex differences adjusting for potential confounders (age and comorbidities).
Results: 14,529 men, mean age 74 ± 11 years and 14,524 women, mean age 78 ± 11 years were identified.
Mortality risk after admission for HF increased with age and the risk of death was higher among men than women.
Hazard ratio’s (men versus women and adjusted for age and co-morbidity) were 1.21 (95%CI 1.14 to 1.28), 1.26
(95% CI 1.21 to 1.31), and 1.28 (95%CI 1.24 to 1.31) for 28 days, 1 year and 5 years mortality, respectively.
Conclusions: This study clearly shows age- and gender differences in short- and long-term risk of death after first
hospitalization for HF with men having higher short- and long-term risk of death than women. As our study
population includes both men and women from all ages, the estimates we provide maybe a good reflection of
‘daily practice’ risk of death and therefore be valuable for clinicians and policymakers.
Background
Heart failure (HF) is a significant and growing health
problem, because of the combination of an ageing popu-
lation and more effective treatment of its major precur-
sor, myocardial infarction [1]. The prevalence of heart
failure, a dominant cause of hospitalization in men and
women > 65 years in Western population, is estimated
to increase from 0.7% for those 45 to 54 years of age to
8.4% for those aged 75 years or older [2].
Current models that are used for the evaluation of the
cost-effectiveness and impact on outcomes of heart fail-
ure management programmes or predicting the burden
on the health care system use overall mortality risks
extracted from studies without detailed information on
gender- and age-specific mortality or assumptions con-
cerning death rates are made [3-5]. However, age and
gender appear to be important predictors of mortality in
hospitalized HF patients [6].
Studies presenting short- and long-term mortality risks
stratified by age and gender are scarce. Most available
studies present the impact of age and gender on mortality
using relative risks or hazard ratios, without providing
stratified and detailed mortality risks for age and gender
subgroups [6-8]. Some studies reported stratified mortal-
i t yr i s k s ,b u tt h e s ew e r em o s tly limited to either age or
gender [9-12]. Two studies were identified that reported
stratified mortality risks by age and gender [13,14]. How-
ever, these studies were restricted to short-term risk of
death. Only one study could be identified that presented
both short- and long-term risk of death stratified by age
and gender [10]. However, this study did not include
patients from all ages. Therefore, the purpose of the pre-
sent study was to estimate detailed short- and long-term
mortality risks stratified by age and gender in a large
nationwide cohort of patients first hospitalized for HF,
including both men and women from all ages.
Methods
For the present study, cohorts were drawn from 1997
a n d2 0 0 0 .T h ec h o i c eo ft h e s et w oy e a r sw a sb a s e do n
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any medium, provided the original work is properly cited.pragmatic reasons at the time of the initiation of the pro-
ject in 2001. The total population of the Netherlands in
1997 and 2000 was 15,567,107 (men 7,696,803, women
7,870,304) and 15,863,950 (men: 7,846,317, women: 8,017,
633), respectively. Approximately 14% of the population
was older than 65 years. To construct a cohort of patients
admitted for the first time because of HF, information
from the national Hospital Discharge Registry (HDR) and
the Dutch Population Registry (PR) were linked. Informa-
tion on cause of death was derived from the Cause of
Death Registry of Statistics Netherlands. The registries
(which are partly openly available) and linkage procedures
have been previously described in detail [15]. In brief, the
HDR is a database on admissions, not persons. For each
hospital admission a new record is created in the HDR.
Following individuals over time based on HDR-informa-
tion alone is troublesome due to difficulties in identifica-
tion of different admissions from the same person in time
and admissions for the same condition at another hospital
(due to referral or to address changes). Yet, linkage (link-
age variables date of birth, gender and 4 digits of postal
code) with the PR can overcome these issues.
Study population
All hospital admissions for HF (ICD-9-CM code 402,
428) between January 1
st and December 31
st, 1997 and
January 1
st and December 31
st, 2000, were selected from
the HDR (which was previously linked with PR). There
were 43,738 hospital admissions. In case of multiple HF
admissions for an individual within the same year we
only used the first admission, yielding a total of 37,386
heart failure patients. Subsequently, information was col-
lected on hospital admission that may have occurred pre-
viously (1995-1997 (data earlier than 1995 were not
available since linkage with PR is only possible from 1995
onwards) and 1995-2000, respectively) for the same con-
dition. Those with a previous admission for heart failure
were excluded (n = 8,333). This resulted in a cohort con-
sisting of 29,053 patients with a first hospitalization for
heart failure in 1997 or 2000 in the Netherlands.
Co-morbidity
T h ep r e s e n c eo fc o - m o r b i d i t y( c a r d i o v a s c u l a rd i s e a s e
(ICD-9-CM codes 390-459) or diabetes mellitus (ICD-9-
CM code 250)) was determined on the basis of the dis-
charge diagnosis of previous hospital admissions or on
the basis of a secondary diagnosis at the moment of the
index admission. No information on severity of disease,
risk factors (hypertension, smoking) or medication use
was available in the registry.
Follow-up
Information on mortality of the patients was obtained by
linkage of the cohort with national Cause of Death
Register. Linkage of the PR (with which the HDR cohort
was previously linked) with the Cause of Death Register
(Statistics Netherlands) was performed using a unique
identification key and therefore was almost complete.
Patients were censored if they migrated out of the
Netherlands or if their linkage key was not unique any-
more during follow-up. Death was coded using the tenth
revision of the International Classification of Disease
(ICD-10).
Data analysis
We analyzed mortality from all causes by examining the
proportion of patients that died within 28-days, 1-year,
and 5-years after their first admission for heart failure.
Survival time was calculated as the time from the
initial admission date in 1997 or 2000 for HF to the
date of death from any cause or to the date that a
patient was censored, which ever came first. The crude
short-term (28 day), 1 year and long-term (5-year) mor-
tality was computed by age and gender according to the
actuarial life table method and expressed as percentages.
The mortality rate in men was compared to mortality
rate in women by calculating relative risks (with 95%
CI). Cox regression models were used for each period to
study differences between men and women in their risk
of death with and without adjusting for potential con-
founders (age and previous admissions for cardiovascu-
lar disease or diabetes mellitus). Data were analyzed
with SPSS software, version 14.0 (SPSS Inc, Chicago,
Illinois, USA). All analyses were performed in agreement
with privacy legislation in the Netherlands [16].
Results
A total of 29,053 patients (mean age 76 ± 11) with a
first hospitalization for congestive heart failure in 1997
or 2000 were identified. General characteristics are pro-
vided in Table 1. Eighteen, 38% and 67% of all men and
27%, 36% and 66% of all women died within 28 days, 1-
year and 5 years, respectively.
Cause of death
Cardiovascular disease was the most frequent cause of
death at 28-days, 1-year and 5-year (table 2). The contri-
bution of cardiovascular diseases as cause of death
decreased with increasing follow-up time while the con-
tribution of cancer as a cause of death increased.
28 day mortality
Short term mortality risk increased with age in men and
women (from 7.5% in men younger than 55 years to
32.9% in men older than 85 years and from 6.9% in
women younger than 55 years to 27.2% in women older
than 85 years). Higher mortality rates in men compared
to women were found across all ages above 65 years
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and women (hazard ratio 0.99; 95% CI 0.94 to 1.05).
However, after adjustment for potential confounders
(age, previous admission for cardiovascular diseases or
diabetes mellitus) mortality was higher in men than in
women (hazard ratio 1.21; 95% CI 1.14 to 1.28) (Table 4).
One-year mortality
One-year mortality risk increased with age in men and
w o m e n( f r o m1 7 . 2 %i nm e ny o u n g e rt h a n5 5y e a r st o
58.6% in men older than 85 years and from 14.9% in
women younger than 55 years to 49.9% in women older
than 85 years). One-year mortality was higher in men
than in women across all ages above 65 years (Table 3).
The crude overall mortality was similar for men and
women at 1 year (hazard ratio 1.04; 95% CI 1.00 to
1.08). However, after adjustment for potential confoun-
ders mortality was higher for men compared to women
(Table 4).
Five-year mortality
Five-year mortality risk increased with age in men and
w o m e n( f r o m3 4 . 2 %i nm e ny o u n g e rt h a n5 5y e a r st o
87.1% in men older than 85 years and from 27.6% in
women younger than 55 years to 84.1% in women older
than 85 years). A higher mortality in men compared to
women was found across all ages; but this difference
was not statistically significant for men and women
between 60 and 64 years (Table 3). After adjustment for
potential confounders overall five-year mortality was
higher for men compared to women (Table 4).
Discussion
The present study using a nationwide cohort of 29,053
patients first hospitalized for heart failure shows clear
age- and gender differences in short- and long-term
mortality risk.
We describe a high mortality over a follow-up of 5
years with men having a higher short- and long-term
risk of death than women.
Overall mortality risks are presented in several popula-
tion based cohort studies and in intervention studies
Table 1 Characteristics of patients with a hospital
admission for heart failure in 1997 or 2000
Men Women Total
Number of patients 14,529 14,524 29,053
Age at admission (years)
Mean 74 78 76
Standard deviation 11 11 11
Prior co-morbidities (%)
cardiovascular disease 44.2 37.5 40.9
- ischemic heart disease 21.0 15.0 18.0
- acute myocardial infarction 9.8 7.5 8.6
- stroke 3.2 3.3 3.2
- peripheral arterial disease 7.9 4.6 6.2
- other cardiovascular disease 24.7 22.5 23.6
diabetes mellitus 15.1 20.4 17.8
Type of hospital (%)
- academic 13.0 9.9 11.5
Length of stay (days) 12 13 12
Origin (%)
-native Dutch 90 89 89
Table 2 Causes of death of patients during follow-up after hospital admission for heart failure in the Netherlands
28 days 1-year 5-years
Cause of death Men
(n = 2,644)
Women
(n = 2,661)
Men
(n = 5,455)
Women
(n = 5,273)
Men
(n = 9,677)
Women
(n = 9,558)
Co-morbidities (%)
Cardiovascular diseases 65.2 70.2 62.8 65.9 59.2 60.6
- ischemic heart disease 29.9 24.8 28.2 22.3 26.3 20.0
- AMI 16.6 14.9 14.5 13.0 13.1 11.1
- congestive heart failure 17.0 21.4 14.7 18.0 12.6 15.7
- stroke 2.3 3.2 3.0 4.3 3.7 5.3
- peripheral arterial diseases 1.9 1.2 2.7 1.9 3.2 2.2
- other cardiovascular diseases 14.1 19.6 14.1 19.3 13.5 17.7
Cancer 7.4 4.8 9.8 6.7 11.2 7.5
- lung cancer 2.2 0.6 3.3 0.7 3.6 0.8
Diseases of respiratory system 14.8 10.5 13.1 9.2 13.0 10.0
- COPD 7.3 4.6 6.9 4.3 6.6 4.4
Complications from DM 2.5 3.6 3.2 4.8 3.8 5.5
AMI: acute myocardial infarction, COPD: chronic obstructive respiratory disease, DM: diabetes mellitus.
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overall short- and long-term mortality risks were pre-
sented in population based cohorts [17,18]. The ARIC
study [19] however, reported lower short- and long-
term mortality risk. Though patients were considerable
younger in the ARIC study (mean age 57 years versus
76 years). Trials [20-23] also report lower mortality risks
(1-year mortality risks ranged from 8 to 31% compared
to 37%). This likely reflects the younger age and less co-
morbidity of patients participating in trials evaluating
the effect of drug treatment for HF [24-26].
The limited available age- and gender specific data
show that the Swedish short-term mortality risks were
lower, the Scottish short- and long-term mortality risks
were higher [10], whereas in the United States 30-day
mortality risks were lower while 1-year mortality risks
were similar [13]. The differences in mortality risk
between the countries might reflect differences in health
care system and treatment as well as differences in
patient characteristics. The latter however remains a
matter of speculation since we had no information
about the medication prescribed and limited information
on clinical characteristics of the patients.
The higher mortality risks in men compared to
women reported in this study have also been reported
in previous large epidemiological studies [27]. A better
long-term survival after 10-15 years has been reported
in women across all age groups [28]. In contrast to
these studies, survival was higher in men than in
women in the SOLVD trial [29]. In studies of patients
admitted to hospital, women were found to have a
lower [13,30] or equal mortality [9]. Possible explana-
tions for the association between gender and mortality
risk that have been reported include that men are more
likely than women to have an ischemic etiology of their
heart failure and that ventricular ejection fraction is
higher in female than in male heart failure patients with
a nonischemic cause [30].
Our results provide insight in age-and gender-specific
risk of death following initial admission for heart failure.
Table 3 Mortality risk at 28 days, 1 year and 5 years after first hospital admission (1997 or 2000) for heart failure in
the Netherlands, by age and gender
No. of
men
No. of
women
Age Men Women RR (95% CI) for Men vs
Women
No. of
Deaths
Percentage
Deaths
No. of
Deaths
Percentage
Deaths
28-day
mortality
814 525 <55 61 7.5 36 6.9 1.09 (0.73-1.63)
672 303 55-59 47 7.0 16 5.3 1.32 (0.76-2.30)
1,118 595 60-64 111 9.9 54 9.1 1.09 (0.80-1.49)
1,851 1,107 65-69 195 10.5 116 10.5 1.28 (1.10-1.48)
2,597 1,826 70-74 419 16.1 231 12.7 1.13 (1.01-1.27)
3,058 2,835 75-79 538 17.6 440 15.5 1.29 (1.17-1.41)
2,579 3,208 80-84 667 25.9 645 20.1 1.21 (1.11-1.31)
1,840 4,125 85+ 606 32.9 1,123 27.2 1.21 (1.11-1.31)
1-year
mortality
814 525 <55 140 17.2 78 14.9 1.16 (0.90-1.49)
672 303 55-59 124 18.5 51 16.8 1.10 (0.82-1.48)
1,118 595 60-64 245 21.9 128 21.5 1.02 (0.84-1.23)
1,851 1,107 65-69 507 27.4 245 22.1 1.24 (1.08-1.41)
2,597 1,826 70-74 892 34.3 518 28.4 1.21 (1.11-1.33)
3,058 2,835 75-79 1,205 39.4 940 33.2 1.19 (1.11-1.33)
2,579 3,208 80-84 1,264 49.0 1,255 39.1 1.25 (1.18-1.33)
1,840 4,125 85+ 1,078 58.6 2,058 49.9 1.17 (1.12-1.23)
5-year
mortality
814 525 <55 278 34.2 145 27.6 1.24 (1.05-1.46)
672 303 55-59 273 40.6 102 33.7 1.21 (1.01-1.45)
1,118 595 60-64 521 46.6 250 42.0 1.11 (0.99-1.24)
1,851 1,107 65-69 1,028 55.5 510 46.1 1.21 (1.12-1.30)
2,597 1,826 70-74 1,691 65.1 1,000 54.8 1.19 (1.13-1.25)
3,058 2,835 75-79 2,195 71.8 1,765 62.3 1.15 (1.11-1.20)
2,579 3,208 80-84 2,089 81.0 2,315 72.2 1.12 (1.09-1.15)
1,840 4,125 85+ 1,602 87.1 3,471 84.1 1.03 (1.01-1.06)
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from all ages, the estimates we provide maybe a good
reflection of ‘daily practice’ risk of death and therefore
be valuable for clinicians and policymakers. Further-
more, these results can be used for the evaluation of the
cost-effectiveness and impact on outcomes of heart fail-
ure management programmes that focuses on secondary
prevention.
The strength of our study is the large size of the
cohort obtained from usual care with a large age range
and information on both men and women. Even though
the validity of national registries has been questioned,
several studies have shown that for the Netherlands, the
validity is adequate [31]. Positive predictive values for
the use of ICD-9 code 428 to identify patients with HF
varies between 80.0% [32] and 94.3% [33]. The quality
of the applied linkage strategy has been excellent [31].
The cause of death information used in our study was
not validated by medical records or autopsy. As a result,
the degree of misclassification in the cause of death is
unquantifiable. However, as in almost every study using
data from vital statistics, some degree of misclassifica-
tion is inevitable. In addition, the validity of the Dutch
national Cause of Death registry has been reported to
be higher than the average validity of eight countries in
the European Community [34].
To appreciate the findings of this study the following
issues needs consideration. The search for previous
admissions to maximum of 6 years before, might have
led to that some “first” heart failure patients were actu-
ally recurrent heart failure patients. The risk of recur-
rence is the highest within the first two years (44%
readmission within 6 months [35] and 70% readmission
within 2 years after a first admission for heart failure
[36]). The inclusion of recurrent heart failure patients
may cause overestimation of absolute mortality rates (as
recurrent heart failure patients may be more severe who
are likely to have a higher mortality risk) but its extent
is difficult to quantify.
Conclusions
In conclusion, this study clearly shows age- and gender
differences in short- and long-term risk of death after
first hospitalization for heart failure with men having a
higher short- and long-term risk of death than women.
As our study population includes both men and women
from all ages, the estimates we provide maybe a good
reflection of ‘daily practice’ risk of death and therefore
be valuable for clinicians and policymakers.
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